Arrowhead received a milestone payment from Sarepta regarding their collaboration. Separately, Sanofi signed an asset purchase agreement with an Arrowhead subsidiary.
2 reports, 1 independent
Updated Aug 8
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Arrowhead received a milestone payment from Sarepta regarding their collaboration. Separately, Sanofi signed an asset purchase agreement with an Arrowhead subsidiary.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Arrowhead Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Sarepta Therapeutics
biopharmaceutical company
Nothing else this week.
-
Sanofi
company in Milan, Italy
Nothing else this week.
Coverage
Newest first; wire copies grouped- Business WireArrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results - Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET PASADENA, Calif., August 07, 2025--(BUSINESS WIRE)--Arrowhead
- Business WireArrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Sanofi to pay $130 million upfront and up to $265 million in potential regulatory m